# Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
Canonical URL: https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-pharmaceuticals-to-advance-the-development-of-soquelitinib-in-china
Ticker: CRVS
Company: Corvus Pharmaceuticals
Source: Corvus Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.corvuspharma.com
## Summary

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) --

## Article Body
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-25 13:46 EST — [Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-pharmaceuticals-to-advance-the-development-of-soquelitinib-in-china) — Source: Corvus Pharmaceuticals
- 2026-06-25 13:46 EST — [Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Corvus Pharmaceuticals
- 2026-06-25 13:46 EST — [Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals
- 2026-06-25 13:46 EST — [Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Corvus Pharmaceuticals
- 2026-06-25 13:46 EST — [Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-announce-results-from-cohort-4-of-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis) — Source: Corvus Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)